CHI Short Course Announced – Development of Neutralizing Antibody Assays

Sept. 22, 2011 - PRLog -- CHI will hold the following pre-conference short course prior to the start of its Immunogenicity Summit 2011.  The course will be held on Tuesday, November 15 from 1:30 – 5:00 p.m.

Development of Neutralizing Antibody Assays

Neutralizing antibodies not only affect efficacy of the therapeutic but also pose the danger of cross-reacting antibodies and ensuing adverse reactions. This interactive session is designed to enable attendees to work out how to design, develop and validate their assays for neutralizing antibodies, and to interpret the results. Attendees are encouraged to contribute with their own experiences and to bring questions for discussion.

The following topics will be covered:

* Strategy for design, development and validation
* Challenges to anticipate
* Interpretation of results
* Emerging trends
* Clinical implementation
* Regulatory guidance and guidelines

Instructors:
Deborah Finco, Ph.D., Immunogenicity Lead, Immunotoxicology COE, Drug Safety R&D, Pfizer, Inc.
Jaya Goyal, Ph.D., Senior Scientist, Clinical Science & Technology, Biogen Idec, Inc.

For more information and to register, please visit http://www.healthtech.com/imn. CHI will reward advance summit registrations up until October 7.

About Cambridge Healthtech Institute (www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

Contact:
James Prudhomme
Cambridge Healthtech Institute
781-972-5400
jprudhomme@healthtech.com